ArticleWorld journal of urology2018
The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer.
Article in World journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Penile cancer: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.ESMO open · 2024Guideline
- Neoadjuvant Treatment for Penile Cancer: A Systematic Review of Contemporary Evidence.Cancers · 2026Review
- From biology to morphology and treatment: the current role of pathology in penile cancer - a narrative review.Frontiers in oncology · 2026Review
- Single-cell transcriptomic profiling reveals distinct tumor microenvironments in HPV-associated penile squamous cell carcinoma.Precision clinical medicine · 2025Article
- Treatment strategies in human papillomavirus-related advanced penile cancer.Nature reviews. Urology · 2025Review
- Emerging Advances in the Molecular Landscape of Penile Cancer and Their Implications for Precision Medicine.Current treatment options in oncology · 2025Review
- HPV and Penile Cancer: Epidemiology, Risk Factors, and Clinical Insights.Pathogens (Basel, Switzerland) · 2024Review
- Human Papillomavirus Infection in Penile Cancer: Multidimensional Mechanisms and Vaccine Strategies.International journal of molecular sciences · 2023Review
- Therapeutic Approaches to Penile Cancer: Standards of Care and Recent Developments.Research and reports in urology · 2023Review
- The relationship of human papillomavirus positivity with tumor characteristics in an Irish penile cancer population.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Combination of Pembrolizumab and Stereotactic Body Radiation Therapy in Recurrent Metastatic Penile Squamous Cell Carcinoma: A Case Study.Biomedicines · 2022Article
- Updates in the use of radiotherapy in the management of primary and locally-advanced penile cancer.Asian journal of urology · 2022Review
- Penile cancer: Updates in systemic therapy.Asian journal of urology · 2022Review
- Patient reported outcomes in advanced penile cancer.Urologic oncology · 2022Article
- An update on treatment of penile cancer.Therapeutic advances in medical oncology · 2022Review
- Urological Cancers and Kidney Transplantation: a Literature Review.Current urology reports · 2021Review
- National trends and survival outcomes of penile squamous cell carcinoma based on human papillomavirus status.Cancer medicine · 2021Article
- Adding radiotherapy based on chemotherapy can improve cancer-specific survival in N3 penile cancer: a SEER-based study.Translational andrology and urology · 2020Article
- Secondary NK/T cell lymphoma after radiotherapy for non-HPV-related squamous cell carcinoma of the penis: an early warning event and literature review.International journal of clinical and experimental pathology · 2020Article
- Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes.European urology focus · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPenile cancer (PeCa) is a rare, aggressive malignancy often associated with the human papillomavirus (HPV). The practice of a personalized risk-adapted approach is not yet established. This study is to assess the relationship between HPV tumor status and chemoradiotherapy (CRT) in PeCa locoregional control (LRC).
methodsWe retrospectively identified patients with HPV status who were diagnosed with squamous cell carcinoma of the penis and treated with surgical resection between 1999 and 2016. The relationship between tumor/treatment characteristics and LRC were analyzed with univariate and multivariate Cox proportional hazard regression analysis (UVA and MVA, respectively). Time-to-event outcomes were estimated with Kaplan-Meier curves and compared via log-rank tests.
resultsFifty-one patients were identified. The median follow-up was 36.6 months. Patients were primarily HPV-negative (HPV-) (n = 28, 55%), and pathologic node positive (pN+) (55%). The 2 year LRC rate was 54%. pN+ patients had a significantly lower 2 year LRC (37 vs. 81%, p = 0.002). In the subgroup analysis of pN+ patients (n = 28), there was a LRC benefit associated with the addition of CRT (HR 0.19; 95% CI 0.05-0.70, p = 0.012) and HPV-positive (HPV+) disease (HR 0.18; 95% CI 0.039-0.80, p = 0.024) using MVA. HPV+ patients treated with CRT had improved 2 year LRC compared to HPV- patients (83 vs. 38%, p = 0.038).
conclusionsAdjuvant CRT and HPV+ disease independently predicted for improved LRC in pN+ PeCa. In HPV+ PeCa, the LRC benefit was primarily observed in patients treated with adjuvant CRT. Prospective investigation of HPV+ and CRT is required to further delineate their roles in optimizing PeCa treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.